Blog

Elvina Almuradova: EMBER-3 trial highlights imlunestrant for metastatic breast cancer

Elvina Almuradova/X

Dec 15, 2024, 10:54

Elvina Almuradova: EMBER-3 trial highlights imlunestrant for metastatic breast cancer

Elvina Almuradova, Associate Professor at Medicana Health Group, posted the following on LinkedIn:

“The EMBER-3 trial evaluated the effectiveness of imlunestrant, a novel oral selective estrogen receptor degrader (SERD), in patients with HR+/HER2- metastatic breast cancer.

Key Findings:

1. Imlunestrant vs Standard Endocrine Therapy:

For patients with ESR1 mutations, imlunestrant improved progression-free survival (PFS): 5.5 months vs 3.8 months with standard endocrine therapy.
No PFS benefit was observed in patients without ESR1 mutations.

2. Combination Therapy (Imlunestrant + Abemaciclib) vs Imlunestrant Alone:

Imlunestrant + Abemaciclib demonstrated superior PFS in all patients: 9.4 months vs 5.5 months (43% reduction in the risk of progression or death).
This benefit was consistent regardless of ESR1 mutation status.

Safety Profile:

Common side effects of imlunestrant: fatigue, diarrhea, nausea, and joint pain.”

Abemaciclib breast cancer therapy cancer Elvina Almuradova EMBER-3 trial ESR1 mutations estrogen receptor degrader HR-/HER2+ Imlunestrant metastatic breast cancer OncoDaily Oncology oncology research progression-free survival

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer